Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients

被引：0
作者：
Negar Nouri
Valiollah Mehrzad
Zahra Khalaj
Erfan Zaker
Fateme Zare
Elham Abbasi
Maede Khosravi
Seyed Mehdi Kalantar
Mansoor Salehi
机构：
[1] Shahid Sadoughi University of Medical Sciences,Department of Medical Genetics, Faculty of Medicine
[2] Isfahan University of Medical Sciences,Department of Genetics and Molecular Biology, School of Medicine, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non
[3] Isfahan University of Medical Sciences,Communicable Disease, Faculty of Medicine
[4] Isfahan University of Medical Sciences,Cancer Prevention Research Center
[5] Shahid Sadoughi University of Medical Sciences,Department of Hematology and Medical Oncology, Faculty of Medicine
[6] Tehran University of Medical Sciences,Reproductive Immunology Research Center
[7] Isfahan University of Medical Sciences,Department of Immunology, School of Public Health
[8] Isfahan University of Medical Sciences,Cellular, Molecular and Genetics Research Center
[9] Shahid Sadoughi University of Medical Sciences,Medical Genetics Research Center of Genome
来源：
Egyptian Journal of Medical Human Genetics | / 24卷
关键词：
BCR-ABL; CML; Drug resistance; Pharmacogenetics; Philadelphia chromosome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 251 条
[1]  
Chorzalska A(2018)Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia Mol Oncol 12 630-647
[2]  
Ahsan N(2016)Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia Tumour Biol 37 791-798
[3]  
Rao RSP(2022)MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis J Oncol Pharm Pract 28 39-48
[4]  
Roder K(2020)Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring Am J Hematol 95 691-709
[5]  
Yu X(2011)Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1 Leuk Lymphoma 52 1980-1990
[6]  
Morgan J(2022)Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring Am J Hematol 97 1236-1256
[7]  
Salimizand H(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 917-927
[8]  
Amini S(2006)Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408-2417
[9]  
Abdi M(2003)Two distinct phosphorylation pathways have additive effects on Abl family kinase activation Mol Cell Biol 23 3884-3896
[10]  
Ghaderi B(2016)Chronic myeloid leukemia: reminiscences and dreams Haematologica 101 541-1942
12345678910